Filing Flows › Comparisons › TRAW vs TVRD
Traws Pharma vs Tvardi Therapeutics: TRAW and TVRD compared
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.6M for Tvardi Therapeutics (Q1 2025). Traws Pharma is growing faster (48× against +20% a year earlier). Traws Pharma is more profitable, with an operating margin of -45.7% against -92.9%.
Where the money goes: TRAW and TVRD
Traws Pharma (TRAW) · Q2 2025
Traws Pharma, Q2 2025: revenue $2.7M (48× year over year), operating margin -45.7%, net loss $915K, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Tvardi Therapeutics (TVRD) · Q1 2025
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Traws Pharma (TRAW) | Tvardi Therapeutics (TVRD) | |
|---|---|---|
| Latest quarter | Q2 2025 | Q1 2025 |
| Revenue | $2.7M | $2.6M |
| Revenue growth, Y/Y | 48× | +20% |
| Operating margin | -45.7% | -92.9% |
| Net earnings | −$915K | −$4.9M |
| Net margin | -33.5% | -191.0% |
| Operating cash flow | −$6.0M | −$4.7M |
Where the revenue comes from
Tvardi Therapeutics
- Other revenue: $1.3M (51%)
- Collaborative revenue: $1.2M (47%)
- Clinical compound revenue: $48K (2%)
Questions
Which is bigger, Traws Pharma or Tvardi Therapeutics?
Traws Pharma is the larger company: $2.7M of revenue in its latest quarter (Q2 2025) against $2.6M for Tvardi Therapeutics (Q1 2025).
Is Traws Pharma or Tvardi Therapeutics growing faster?
Traws Pharma is growing faster (48× against +20% a year earlier).
Which is more profitable, Traws Pharma or Tvardi Therapeutics?
Traws Pharma is more profitable, with an operating margin of -45.7% against -92.9%.
More: Traws Pharma earnings · how Traws Pharma makes money · Tvardi Therapeutics earnings · how Tvardi Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2025; 10-Q filed May 13, 2025). Fiscal quarters can end on different dates. Not investment advice.